Performance of cardiovascular disease risk prediction equations in more than 14 000 survivors of cancer in New Zealand primary care: a validation study.
- Publisher:
- Elsevier
- Publication Type:
- Journal Article
- Citation:
- Lancet, 2023, 401, (10374), pp. 357-365
- Issue Date:
- 2023-02-04
Closed Access
Filename | Description | Size | |||
---|---|---|---|---|---|
1-s2.0-S0140673622024059-main.pdf | Published version | 1.33 MB |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Tawfiq, E | |
dc.contributor.author | Selak, V | |
dc.contributor.author | Elwood, JM | |
dc.contributor.author |
Pylypchuk, R |
|
dc.contributor.author | Tin, ST | |
dc.contributor.author | Harwood, M | |
dc.contributor.author | Grey, C | |
dc.contributor.author | McKeage, M | |
dc.contributor.author | Wells, S | |
dc.date.accessioned | 2024-05-21T21:40:13Z | |
dc.date.available | 2022-11-17 | |
dc.date.available | 2024-05-21T21:40:13Z | |
dc.date.issued | 2023-02-04 | |
dc.identifier.citation | Lancet, 2023, 401, (10374), pp. 357-365 | |
dc.identifier.issn | 0140-6736 | |
dc.identifier.issn | 1474-547X | |
dc.identifier.uri | http://hdl.handle.net/10453/179090 | |
dc.description.abstract | BACKGROUND: People with cancer have an increased risk of cardiovascular disease. Risk prediction equations developed in New Zealand accurately predict 5-year cardiovascular disease risk in a general primary care population in the country. We assessed the performance of these equations for survivors of cancer in New Zealand. METHODS: For this validation study, patients aged 30-74 years from the PREDICT open cohort study, which was used to develop the New Zealand cardiovascular disease risk prediction equations, were included in the analysis if they had a primary diagnosis of invasive cancer at least 2 years before the date of the first cardiovascular disease risk assessment. The risk prediction equations are sex-specific and include the following predictors: age, ethnicity, socioeconomic deprivation index, family history of cardiovascular disease, smoking status, history of atrial fibrillation and diabetes, systolic blood pressure, total cholesterol to HDL cholesterol ratio, and preventive pharmacotherapy (blood-pressure-lowering, lipid-lowering, and antithrombotic drugs). Calibration was assessed by comparing the mean predicted 5-year cardiovascular disease risk, estimated using the risk prediction equations, with the observed risk across deciles of risk, for men and women, and according to the three clinical 5-year cardiovascular disease risk groups in New Zealand guidelines (<5%, 5% to <15%, and ≥15%). Discrimination was assessed by Harrell's C statistic. FINDINGS: 14 263 patients were included in the study. The mean age was 61 years (SD 9) for men and 60 years (SD 8) for women, with a median follow-up of 5·8 years for men and 5·7 years for women. The observed cardiovascular disease risk was underpredicted by a maximum of 2·5% in male and 3·2% in female decile groups. When patients were grouped according to clinical risk groups, observed cardiovascular disease risk was underpredicted by less than 2% in the lower risk groups and overpredicted by 2·2% for men and 3·3% for women in the highest risk group. Harrell's C statistics were 0·67 (SE 0·01) for men and 0·73 (0·01) for women. INTERPRETATION: The New Zealand cardiovascular disease risk prediction equations reasonably predicted the observed 5-year cardiovascular disease risk in survivors of cancer in the country, in whom risk prediction was considered clinically appropriate. Prediction could be improved by adding cancer-specific variables and considering competing risks. Our findings suggest that the equations are reasonable clinical tools for use in survivors of cancer in New Zealand. FUNDING: Auckland Medical Research Foundation, Health Research Council of New Zealand. | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.publisher | Elsevier | |
dc.relation.ispartof | Lancet | |
dc.relation.isbasedon | 10.1016/S0140-6736(22)02405-9 | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | 11 Medical and Health Sciences | |
dc.subject.classification | General & Internal Medicine | |
dc.subject.classification | 32 Biomedical and clinical sciences | |
dc.subject.classification | 42 Health sciences | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Male | |
dc.subject.mesh | Female | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Risk Factors | |
dc.subject.mesh | Cohort Studies | |
dc.subject.mesh | Risk Assessment | |
dc.subject.mesh | Cardiovascular Diseases | |
dc.subject.mesh | New Zealand | |
dc.subject.mesh | Prospective Studies | |
dc.subject.mesh | Proportional Hazards Models | |
dc.subject.mesh | Neoplasms | |
dc.subject.mesh | Primary Health Care | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Neoplasms | |
dc.subject.mesh | Cardiovascular Diseases | |
dc.subject.mesh | Proportional Hazards Models | |
dc.subject.mesh | Risk Assessment | |
dc.subject.mesh | Risk Factors | |
dc.subject.mesh | Cohort Studies | |
dc.subject.mesh | Prospective Studies | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Primary Health Care | |
dc.subject.mesh | New Zealand | |
dc.subject.mesh | Female | |
dc.subject.mesh | Male | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Male | |
dc.subject.mesh | Female | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Risk Factors | |
dc.subject.mesh | Cohort Studies | |
dc.subject.mesh | Risk Assessment | |
dc.subject.mesh | Cardiovascular Diseases | |
dc.subject.mesh | New Zealand | |
dc.subject.mesh | Prospective Studies | |
dc.subject.mesh | Proportional Hazards Models | |
dc.subject.mesh | Neoplasms | |
dc.subject.mesh | Primary Health Care | |
dc.title | Performance of cardiovascular disease risk prediction equations in more than 14 000 survivors of cancer in New Zealand primary care: a validation study. | |
dc.type | Journal Article | |
utslib.citation.volume | 401 | |
utslib.location.activity | England | |
utslib.for | 11 Medical and Health Sciences | |
pubs.organisational-group | University of Technology Sydney | |
pubs.organisational-group | University of Technology Sydney/Faculty of Health | |
utslib.copyright.status | closed_access | * |
dc.date.updated | 2024-05-21T21:40:11Z | |
pubs.issue | 10374 | |
pubs.publication-status | Published | |
pubs.volume | 401 | |
utslib.citation.issue | 10374 |
Abstract:
BACKGROUND: People with cancer have an increased risk of cardiovascular disease. Risk prediction equations developed in New Zealand accurately predict 5-year cardiovascular disease risk in a general primary care population in the country. We assessed the performance of these equations for survivors of cancer in New Zealand. METHODS: For this validation study, patients aged 30-74 years from the PREDICT open cohort study, which was used to develop the New Zealand cardiovascular disease risk prediction equations, were included in the analysis if they had a primary diagnosis of invasive cancer at least 2 years before the date of the first cardiovascular disease risk assessment. The risk prediction equations are sex-specific and include the following predictors: age, ethnicity, socioeconomic deprivation index, family history of cardiovascular disease, smoking status, history of atrial fibrillation and diabetes, systolic blood pressure, total cholesterol to HDL cholesterol ratio, and preventive pharmacotherapy (blood-pressure-lowering, lipid-lowering, and antithrombotic drugs). Calibration was assessed by comparing the mean predicted 5-year cardiovascular disease risk, estimated using the risk prediction equations, with the observed risk across deciles of risk, for men and women, and according to the three clinical 5-year cardiovascular disease risk groups in New Zealand guidelines (<5%, 5% to <15%, and ≥15%). Discrimination was assessed by Harrell's C statistic. FINDINGS: 14 263 patients were included in the study. The mean age was 61 years (SD 9) for men and 60 years (SD 8) for women, with a median follow-up of 5·8 years for men and 5·7 years for women. The observed cardiovascular disease risk was underpredicted by a maximum of 2·5% in male and 3·2% in female decile groups. When patients were grouped according to clinical risk groups, observed cardiovascular disease risk was underpredicted by less than 2% in the lower risk groups and overpredicted by 2·2% for men and 3·3% for women in the highest risk group. Harrell's C statistics were 0·67 (SE 0·01) for men and 0·73 (0·01) for women. INTERPRETATION: The New Zealand cardiovascular disease risk prediction equations reasonably predicted the observed 5-year cardiovascular disease risk in survivors of cancer in the country, in whom risk prediction was considered clinically appropriate. Prediction could be improved by adding cancer-specific variables and considering competing risks. Our findings suggest that the equations are reasonable clinical tools for use in survivors of cancer in New Zealand. FUNDING: Auckland Medical Research Foundation, Health Research Council of New Zealand.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph